{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:27:06Z","timestamp":1790616426117,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T00:00:00Z","timestamp":1365120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2013,9]]},"abstract":"\n Aims<\/jats:title>\n \n To determine whether baseline characteristics, especially haemoglobin A1c (\n HbA1c<\/jats:styled-content>\n ), predict the likelihood of reaching\n HbA1c<\/jats:styled-content>\n \u2009\u2264\u20097.0% or the risk of experiencing hypoglycaemia after the addition of insulin glargine to oral therapy in type 2 diabetes.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Pooled patient\u2010level data from 12 prospective, randomized, controlled studies that used insulin glargine in a treat\u2010to\u2010target titration regimen seeking fasting glucose levels \u22645.5\u2009mmol\/l (100\u2009mg\/dl) were analysed. Baseline characteristics were evaluated by logistic regression models as predictors of reaching a target\n HbA1c<\/jats:styled-content>\n \u2009\u2264\u20097.0% or experiencing confirmed hypoglycaemia. The effect of prior glycaemic control was further explored by analysis of categorical ranges of baseline\n HbA1c<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 2312 participants, 95% completed 24\u2009weeks of treatment. Lower\n HbA1c<\/jats:styled-content>\n at baseline was independently associated with reaching\n HbA1c<\/jats:styled-content>\n target [adjusted odds ratio (\n OR<\/jats:styled-content>\n ) for 1% difference: 0.538, p\u2009<\u20090.0001] and also with likelihood of experiencing confirmed hypoglycaemic events (adjusted\n OR<\/jats:styled-content>\n : 0.835, p\u2009<\u20090.0001) at week 24. In an unadjusted analysis by baseline\n HbA1c<\/jats:styled-content>\n range, the strong association between baseline control and attaining target\n HbA1c<\/jats:styled-content>\n was confirmed (75% with baseline\n HbA1c<\/jats:styled-content>\n \u2009<\u20098.0%, 60% with baseline\n HbA1c<\/jats:styled-content>\n \u2009\u2265\u20098.0 and <9.0% and 38% with baseline\n HbA1c<\/jats:styled-content>\n \u2009\u2265\u20099.0% attained\n HbA1c<\/jats:styled-content>\n \u2009\u2264\u20097.0%). The incidence of hypoglycaemia confirmed <3.9\u2009mmol\/l (70\u2009mg\/dl) was higher in the lower baseline\n HbA1c<\/jats:styled-content>\n ranges but severe hypoglycaemia was infrequent at all baseline\n HbA1c<\/jats:styled-content>\n levels.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Systematically titrated insulin glargine, added to oral agents, was effective over a wide range of baseline\n HbA1c<\/jats:styled-content>\n . Lower baseline\n HbA1c<\/jats:styled-content>\n was the best clinical predictor of achieving\n HbA1c<\/jats:styled-content>\n \u2009\u2264\u20097.0% and also associated with higher risk of glucose\u2010confirmed hypoglycaemia. Severe hypoglycaemia was infrequent using this treatment approach.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12096","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T02:55:05Z","timestamp":1363229705000},"page":"819-825","source":"Crossref","is-referenced-by-count":44,"title":["Baseline\n HbA1c<\/scp>\n predicts attainment of 7.0%\n HbA1c<\/scp>\n target with structured titration of insulin glargine in type 2 diabetes: a patient\u2010level analysis of 12 studies"],"prefix":"10.1111","volume":"15","author":[{"given":"M. C.","family":"Riddle","sequence":"first","affiliation":[{"name":"Department of Medicine Oregon Health & Science University Portland OR USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vlajnic","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sanofi U.S. Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zhou","sequence":"additional","affiliation":[{"name":"Medpace, Inc. Cincinnati OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes and Endocrine Center at Medical City Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,5]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9025"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP.15.6.540"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3080"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc05-1365"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0911-x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905479"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01881.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-925222"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.2.254"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60485-7"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1357"},{"issue":"1","key":"e_1_2_7_13_1","first-page":"A139","article-title":"Early initiation of insulin glargine versus lifestyle management in people with type 2 diabetes and A1c of 7\u20138%","volume":"57","author":"Blickle J\u2010F","year":"2008","journal-title":"Diabetes"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0132-0"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.29.03.06.dc05-0695"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP09281.OR"},{"key":"e_1_2_7_17_1","unstructured":"Determine whether glycemic control is different between Lantus & a 3rd oral agent when failure with other treatment. Available from URL:http:\/\/clinicaltrials.gov\/show\/NCT00046462. Accessed 26 October 2011."},{"key":"e_1_2_7_18_1","unstructured":"Lantus versus Humalog Mix as add\u2010on therapy in type diabetes patients failing sulfonylurea and metformin combination treatment. Available from URL:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01336751. Accessed 26 October 2011."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1988.tb01003.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2003.00259.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.11.2590"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2008.04.063"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1911"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.02941.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1120"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02847.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjr.0000124326.85096.ec"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.460"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2082"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12096","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:58:37Z","timestamp":1761872317000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,5]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1111\/dom.12096"],"URL":"https:\/\/doi.org\/10.1111\/dom.12096","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,5]]}}}